anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The COVID-19 pandemic has caused 14.83 million deaths globally. This systematic review and meta-analysis aimed to provide a pooled estimate of the overall mortality and morbidity of critically ill COVID-19 patients.
METHOD: Four electronic databases, Medline/PubMed, the Cochrane Library, the WHO COVID-19 database, and the Web of Science, were used to identify relevant studies. Two authors independently screened the studies, evaluated the eligibility criteria and resolved discrepancies through discussion with the third author. The pooled effect size was computed using STATA software version 14. The Cochran Q test and I2 test were utilized to assess heterogeneity across the studies. Additionally, subgroup analysis, sensitivity analysis, and publication bias were evaluated. It is registered in Prospero with Prospero ID CRD42020212146.
RESULTS: A total of 1003 published articles were screened from various databases, and 24 studies involving a total of 142,291 critically ill COVID-19 participants were selected for inclusion in the review. Among the participants, 67 % were male, and the mean age was 63.43 + SD3.33 years. The mortality rate reported in the individual studies ranged from 4.5 % to 69.5 %. The findings from the analysis revealed that the overall pooled mortality rate was 34 % (95 % confidence interval: 31 %-37 %). Additionally, the findings showed that 62 % of critically ill COVID-19 patients required mechanical ventilation, while 68.7 % of these patients had chronic disease comorbidities.
CONCLUSION: Critically ill COVID-19 patients face a high-risk risk of death, with an estimate of about one in three patients dying from the virus. Notably, a substantial portion of critically ill COVID-19 patients (62 %) require mechanical ventilation; surprisingly, more than two-thirds of patients with COVID-19 have chronic disease comorbidities, highlighting the importance of managing comorbidities in this population.
Participants receive oral placebo four times daily for 5 days in week 2 and oral PEITC four times daily for 5 days in week 4. Participants are also asked to smoke only deuterated NNK cigarettes, record the number of cigarettes smoked and alcoholic drinks consumed each day, and keep a food and beverage diary as in arm I.
Ocular melanoma, including uveal melanoma (UM) and conjunctival melanoma (CM), is the most common ocular cancer among adults with a high rate of recurrence and poor prognosis. Loss of epigenetic homeostasis disturbed gene expression patterns, resulting in oncogenesis. Herein, we comprehensively analyzed the DNA methylation, transcriptome profiles, and corresponding clinical information of UM patients through multiple machine-learning algorithms, finding that a methylation-driven gene RBMS1 was correlated with poor clinical outcomes of UM patients. RNA-seq and single-cell RNA-seq analyses revealed that RBMS1 reflected diverse tumor microenvironments, where high RBMS1 expression marked an immune active TME. Furthermore, we found that tumor cells were identified to have the higher communication probability in RBMS1+ state. The functional enrichment analysis revealed that RBMS1 was associated with pigment granule and melanosome, participating in cell proliferation as well as apoptotic signaling pathway. Biological experiments were performed and demonstrated that the silencing of RBMS1 inhibited ocular melanoma proliferation and promoted apoptosis. Our study highlighted that RBMS1 reflects a distinct microenvironment and promotes tumor progression in ocular melanoma, contributing to the therapeutic customization and clinical decision-making.
The present invention discloses a compound of an Terbinafine or the halo-Terbinafine membrane forming gel, which comprises the components of the following weight percentages comprising 0.5 percentage to 7 percentage of alkyl cellulose, 1 percentage to 10 percentage of etherifying agent, 0.5 percentage to 5 percentage of cross linking agent, 0.5 percentage to 5 percentage of accentuator, 75 percentage to 90 percentage of dissolvant0.1 percentage to 5 percentage, of Terbinafine or the halo-Terbinafine. The cross linking agent is the saturated fat or the alcoholic acid, the chemical general formula of which is C<SUB>n</SUB>H<SUB>2n+2-m-l</SUB>(OH)<SUB>m</SUB>(COOH)<SUB>l</SUB>. Among the formula, m or n or 1 is the integer and the n is no less than m, which is no less than 2. 1 is no less than 0 and the result of m plus 1 is 4 to 8. The result of n plus 1 is 4 to 8. In the present invention, the compound of the Terbinafine or the halo-Terbinafine local membrane forming gel is applied for treatment of the local fungus inflammation. A water drain protective membrane with smooth property, firm property, wear-resisting property and duration property is formed on the surface of the ulcer when the present invention is applied. Compared with all kinds of formulations of the Terbinafine or the halo-Terbinafine in the present technique, the membrane formed by the gel compound is not likely to experience fracture, dissolution or corrosion. The membrane has the properties of long maintenance time and slow releasing of the medicine.
Safyral contains 3 mg of the progestin DRSP, which has anti-mineralocorticoid activity, including the potential for hyperkalemia in high-risk patients, comparable to a 25 mg dose of spironolactone. Safyral is contraindicated in patients with conditions that predispose to hyperkalemia (that is, renal impairment, hepatic impairment, and adrenal insufficiency). Women receiving daily, long-term treatment for chronic conditions or diseases with medications that may increase serum potassium concentration should have their serum potassium concentration checked during the first treatment cycle. Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin–II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDs. Consider monitoring serum potassium concentration in high-risk patients who take a strong CYP3A4 inhibitor long-term and concomitantly. Strong CYP3A4 inhibitors include azole antifungals (e.g. ketoconazole, itraconazole, voriconazole), HIV/HCV protease inhibitors (e.g., indinavir, boceprevir), and clarithromycin [see Clinical Pharmacology (12.3)].
A natural human shaker hair is offered to be efficiently applied to the balding spots and thinning areas of a user's scalp. The shaker hair comprises 100% natural human hairs and does not include any chemicals and/or man-made materials. The shaker hair is statically charged with negative electricity to not only allow easy application to the affected areas, but also cling to the user's scalp and existing hair. Thus, the shaker hair creates root lift and substantial kickstand support to the existing long hair of the user, and helps the user with desired styling. Further, an innovative method of making the all-natural human shaker hair is provided. The method prepares the shaker hair by cutting natural human hairs into hair granules and charging the hair granules with a charging machine. The resulting shaker hair charged with statically negative charge is placed into hair shakers and ready for use.
In this quasi experimental study, 30 patients aged 40-80 years of either gender with a confirmed diagnosis of COVID-19 receiving supplemental oxygen were recruited from DHQ Hospital Faisalabad. patients were grouped into two A \& B. We collected baseline data on demographics and anthropometrics. After baseline data collection, all the patients were helped into the prone position, which was maintained for a minimum duration of three hours. After that patients in group B performed alternate nostril breathing for 10 minutes with help of physiotherapist. Clinical data were re-collected on 3rd day of intervention one hour after returning to the supine position in group A and after alternate nostril breathing in group B. The main study outcome was the variation in oxygenation (partial pressure of oxygen \[PaO2\]/ fractional concentration of oxygen in inspired air \[FiO2\]) between baseline and resupination, and General psychological state through GAD-7 General anxiety disorder questionnaire.
Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.
PROBLEM TO BE SOLVED: To obtain a cosmetic whcih stabilizes the skin or hair cosmetic system and can prevent the smooth touch on using or rinsing from deteriorating with time by including a highly polymerized polyethylene glycol, a water-soluble reducing agent and water. SOLUTION: The cosmetic for preferably skin is obtained by including (A) 0.001-5 wt.% of a highly polymerized polyethylene glycol, (B) 0.001-1 wt.% of a water-soluble reducing agent and (C) water preferably in a proportion of 0.1-99.9 wt.% based on the whole composition. One or more than two kinds selected from hydrogensulfite, sulfite, thiosulfite or thioglycolate are favorable as the component B. This cosmetic is preferably a shampoo or a one pack type cosmetic for hair. It is favorable that the component A has an average molecular weight of 400,000-7,000,000. On this cosmetic, water-soluble polymers, gelling agents such as a natural gum and the like, polyhydric alcohols, moisturizers such as a mucopolysaccharide and the like, higher alcohols, antioxidants or the like can be blended.
Bicillin C-R is intended for Intramuscular Injection ONLY. Do not inject into or near an artery or nerve, or intravenously or admix with other intravenous solutions. (See WARNINGS section).

Administer by DEEP INTRAMUSCULAR INJECTION in the upper, outer quadrant of the buttock (dorsogluteal) or the ventrogluteal site. In neonates, infants and small children, the midlateral aspect of the thigh may be preferable. Administration in the anterolateral thigh is not recommended due to the adverse effects observed (see WARNINGS section), and vascularity of this region. When doses are repeated, vary the injection site.

Because of the high concentration of suspended material in this product, the needle may be blocked if the injection is not made at a slow, steady rate.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Participants in Part 1 will only receive single dose of Treatment A1 oral Suspension (25 milligram \[mg\], Fasted) then Treatment B1 (Direct Compression Tablets, 5\*5 mg Tablets, Fasted) followed by Treatment C1 (Direct Compression Tablets (5\*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
BACKGROUND: There is conflicting evidence on association between quick sequential organ failure assessment (qSOFA) and sepsis mortality in ICU patients. The primary aim of this study was to determine the association between qSOFA and 28-day mortality in ICU patients admitted for sepsis. Association of qSOFA with early (3-day), medium (28-day), late (90-day) mortality was assessed in low and lower middle income (LLMIC), upper middle income (UMIC) and high income (HIC) countries/regions.
METHODS: This was a secondary analysis of the MOSAICS II study, an international prospective observational study on sepsis epidemiology in Asian ICUs. Associations between qSOFA at ICU admission and mortality were separately assessed in LLMIC, UMIC and HIC countries/regions. Modified Poisson regression was used to determine the adjusted relative risk (RR) of qSOFA score on mortality at 28 days with adjustments for confounders identified in the MOSAICS II study.
RESULTS: Among the MOSAICS II study cohort of 4980 patients, 4826 patients from 343 ICUs and 22 countries were included in this secondary analysis. Higher qSOFA was associated with increasing 28-day mortality, but this was only observed in LLMIC (p < 0.001) and UMIC (p < 0.001) and not HIC (p = 0.220) countries/regions. Similarly, higher 90-day mortality was associated with increased qSOFA in LLMIC (p < 0.001) and UMIC (p < 0.001) only. In contrast, higher 3-day mortality with increasing qSOFA score was observed across all income countries/regions (p < 0.001). Multivariate analysis showed that qSOFA remained associated with 28-day mortality (adjusted RR 1.09 (1.00-1.18), p = 0.038) even after adjustments for covariates including APACHE II, SOFA, income country/region and administration of antibiotics within 3 h.
CONCLUSIONS: qSOFA was independently associated with 28-day mortality in ICU patients admitted for sepsis. In LLMIC and UMIC countries/regions, qSOFA was associated with early to late mortality but only early mortality in HIC countries/regions.
The gut plays a crucial role in metabolism by regulating the passage of nutrients, water and microbial-derived substances to the portal circulation. Additionally, it produces incretins, such as glucose-insulinotropic releasing peptide (GIP) and glucagon-like derived peptide 1 (GLP1, encoded by gcg gene) in response to nutrient uptake. We aimed to investigate whether offspring from overweight rats develop anomalies in the barrier function and incretin transcription. We observed pro-inflammatory related changes along with a reduction in Claudin-3 levels resulting in increased gut-permeability in fetuses and offspring from overweight rats. Importantly, we found decreased gip mRNA levels in both fetuses and offspring from overweight rats. Differently, gcg mRNA levels were upregulated in fetuses, downregulated in female offspring and unchanged in male offspring from overweight rats. When cultured with high glucose, intestinal explants showed an increase in gip and gcg mRNA levels in control offspring. In contrast, offspring from overweight rats did not exhibit any response in gip mRNA levels. Additionally, while females showed no response, male offspring from overweight rats did exhibit an upregulation in gcg mRNA levels. Furthermore, female and male offspring from overweight rats showed sex-dependent anomalies when orally challenged with a glucose overload, returning to baseline glucose levels after 120 min. These results open new research questions about the role of the adverse maternal metabolic condition in the programming of impairments in glucose homeostasis, enteroendocrine function and gut barrier function in the offspring from overweight mothers and highlight the importance of a perinatal maternal healthy metabolism.
The invention provides application of garden burnet charcoal in preventing and treating tinea corporis, tinea cruris, tinea manus and tinea pedis, and application of garden burnet charcoal in preparation of medicines or daily necessities. Simultaneously provides the application of one or more components of gallic acid, pyrogallic acid, gallic acid methyl ester, gallic acid ethyl ester and protocatechuic aldehyde in preventing and treating tinea corporis and cruris, tinea manus and pedis, and the application in the preparation of medicines or daily necessities. The present invention shows that the sanguisorba root charcoal can obviously inhibit the growth of tinea corporis, tinea cruris, tinea manus and tinea pedis, and the effect of the sanguisorba root charcoal is equivalent to that of common traditional Chinese medicines of radix sophorae flavescentis and golden larch bark for treating tinea. After the sanguisorba officinalis charcoal is administrated, the growth of trichophyton rubrum is obviously inhibited by ocular observation. Clinical curative effect observation shows that the cure rate of patients after 4 weeks of treatment by 0.5 percent sanguisorba officinalis charcoal gel reaches 96.15 percent, and half of patients are cured. Meanwhile, the main components of the garden burnet, namely gallic acid, pyrogallic acid, gallic acid methyl ester, gallic acid ethyl ester and protocatechuic aldehyde, have remarkable anti-trichophyton rubrum effects, and the contents are not reported.
Disclosed are devices, a system, methods and computer-readable medium products that provide techniques to implement functionality to determine when to softened upper bounds of drug delivery and how much to soften the upper bound. Future blood glucose measurement values may be predicted by calculating deviations between predicted blood glucose measurement values and additional blood glucose measurement values. A gain parameter may be determined for use with a model of predicting a user's blood glucose measurement values and determining future drug dosages. Safety constraints may be determined based on an evaluation of missing blood glucose measurement values. In addition, safety constraints may be determined based on an evaluation of a user's increased interaction with an automatic drug delivery device. A bolus uncertainty metric to determine an amount of insulin to be provided in a bolus dosage in response to a bolus request may be calculated.
Not recommended for children under 3 years of age. In children from 3 to 5 years of age, start with 2.5 mg daily; daily dosage may be raised in increments of 2.5 mg at weekly intervals until optimal response is obtained.

In children 6 years of age and older, start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. Only in rare cases will it be necessary to exceed a total of 40 mg per day. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.

Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.
Alteplase is an enzyme (serine protease) that has the property of fibrin-enhanced conversion of plasminogen to plasmin. It produces limited conversion of plasminogen in the absence of fibrin. Alteplase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin, thereby initiating local fibrinolysis (1).

In patients with acute myocardial infarction administered 100 mg of Activase as an accelerated intravenous infusion over 90 minutes, plasma clearance occurred with an initial half‑life of less than 5 minutes and a terminal half‑life of 72 minutes. Clearance is mediated primarily by the liver (2).

When Cathflo Activase is administered for restoration of function to central venous access devices according to the instructions in DOSAGE AND ADMINISTRATION, circulating plasma levels of Alteplase are not expected to reach pharmacologic concentrations. If a 2 mg dose of Alteplase were administered by bolus injection directly into the systemic circulation (rather than instilled into the catheter), the concentration of circulating Alteplase would be expected to return to endogenous circulating levels of 5–10 ng/mL within 30 minutes (1).
The present invention allows individual providers to be assigned to one or more roles. A role corresponds to a function, service, or action that can be fulfilled by the provider who is assigned to the role. A media session may be initiated by sending a session request from a requester toward a given role instead of being initiated directly to a particular provider. The media session may include a voice or video call, instant messaging session, file transfer session, application sharing session, or the like. The session request is routed to a role server, which may direct the session request to the provider who is assigned to the corresponding role. Once a decision is made to route the session request to a particular provider, provider routing rules may further control how the session requests are routed to the provider terminals of the particular provider.
This product contains potassium and sodium and should be used with caution if regulation of these elements is desired. Occasionally, some individuals may experience a mild laxative effect during the first few days of phosphate therapy. If laxation persists to an unpleasant degree, reduce the daily dosage until this effect subsides or, if necessary, discontinue the use of this product.

Use of this medication should be carefully considered when the following medical problems exist: Cardiac disease (particularly in digitalized patients), Addison's disease, acute dehydration, extensive tissue breakdown, myotonia congenita, cardiac failure, cirrhosis of the liver or severe hepatic disease, peripheral and pulmonary edema, hypernatremia, hypertension, toxemia of pregnancy, hypoparathyroidism, and acute pancreatitis. Rickets may benefit from phosphate therapy, but caution should be observed. High serum phosphate levels increase the risk of extraskeletal calcification.
One of the most important problems of nurses in Turkey is the stress they experience at work. This stress experienced in the workplace is accompanied by consequences such as depression, anxiety, and decreased job satisfaction. Therefore, it is clear that addressing the stress associated with the nursing profession is an urgent problem. The aim of the study, which was planned in the experimental design type, was to determine the effect of the mindfulness-based stress reduction training on nurses' job stress. The sample of the study consisted of 70 nurses (35 in the experimental group, 35 in the control group) working in a university hospital in Çanakkale. The mindfulness-based stress reduction training was carried out as a group, once a week, for 8 weeks in total. The Personal Information Form, the Job Stress Scale, the Mindful Attention Awareness Scale, and the Rosenbaum's Learned Resourcefulness Scale were used for data collection. A total of three follow-ups were conducted to the nurses before the training, at the end of the training, and 3 months after the training. Descriptive analysis, Chi-square test, Independent Samples T-test, Dependent Samples T-test, and one-way analysis of variance were used in the analysis of the research data.
Dasatinib is a kinase inhibitor. The chemical name for dasatinib is N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate. The molecular formula is C22H26ClN7O2S•H2O, which corresponds to a formula weight of 506.02 (monohydrate). The anhydrous free base has a molecular weight of 488.01. Dasatinib has the following chemical structure:

Dasatinib is a white to off-white powder. The drug substance is insoluble in water and slightly soluble in ethanol and methanol, polyethylene glycol 400 and propylene glycol; very slightly soluble in acetone and acetonitrile; and practically insoluble in corn oil. 

Dasatinib tablets are white to off-white, biconvex, film-coated tablets containing dasatinib, with the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate and microcrystalline cellulose. The tablet coating consists of hydroxypropyl cellulose, hypromellose, titanium dioxide and triethyl citrate. Dasatinib tablets are supplied for oral administration.